Showing results (111-120 of 152) with videos related to

Sort By:
Pageof 16
Journal of Hepatology|December 25, 2019
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertensionGuadalupe Garcia-Tsao, Jaime Bosch, Zeid Kayali, et al.
Hepatology (Baltimore, Md.)|February 7, 2014
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infectionDavid L Wyles, Maribel Rodriguez-Torres, Eric Lawitz, et al.
The American Journal of Gastroenterology|August 27, 2019
Variability and Lability of Ammonia Levels in Healthy Volunteers and Patients With Cirrhosis: Implications for Trial Design and Clinical PracticeJasmohan S Bajaj, Patricia Pringle Bloom, Raymond T Chung, et al.
Antimicrobial Agents and Chemotherapy|August 10, 2016
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239Christopher M Owens, Bradley B Brasher, Alex Polemeropoulos, et al.
Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' PerspectiveZobair M Younossi, Homie Razavi, Michael Sherman, et al.
The American Journal of Gastroenterology|September 1, 2021
High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal AdherencePhilippe J Zamor, Ashley Brown, Douglas E Dylla, et al.
Medicine|July 28, 2023
High sustained virologic response rates, regardless of race or socioeconomic class, in patients treated with chronic hepatitis C in community practice using a specialized pharmacy teamSaatchi Kuwelker, Eugenia Tsai, Lily Kuo, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Antimicrobial Agents and Chemotherapy|February 1, 2012
Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis CClaudio Pasquinelli, Fiona McPhee, Timothy Eley, et al.
Pageof 16